glaxosmithkline (ceo)

literal strings: GlaxoSmithkline, Glaxosmithkline, GlaxoSmithKline, glaxosmithkline

categories

NELL has only weak evidence for items listed in grey

• ceo
• SEAL @180 (75.0%) on 16-dec-2010 [ 1 2 ] using glaxosmithkline

relations

NELL has only weak evidence for items listed in grey

• agentcollaborateswithagent
• andrew_witty
• CPL @1095 (93.8%) on 17-jan-2018 [ "arg1 chief executive officer arg2" "arg1 chief executive Sir arg2" "arg1 chief Sir arg2" "arg1 chief executive arg2" ] using (andrew_witty, glaxosmithkline)
• OE @1039 (100.0%) on 02-feb-2017 [ http://www.philly.com/philly/blogs/phillypharma/GlaxoSmithKlines-Andrew-Witty-says-1-billion-price-tag-for-drug-development-is-a-myth.html  ] using (glaxosmithkline, andrew_witty)
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~X0~concept:controlledbyagent" "Y~X0~concept:agentcontrols" "Y~_X0~concept:agentcontrols" "Y~X0~concept:superpartof" "Y~_X0~concept:superpartof" ] using (andrew_witty, glaxosmithkline)
• SEAL @458 (50.0%) on 23-nov-2011 [ 1 ] using (glaxosmithkline, andrew_witty)
• SEAL @458 (50.0%) on 23-nov-2011 [ 1 ] using (andrew_witty, glaxosmithkline)
• CPL @1095 (93.8%) on 17-jan-2018 [ "arg1 chief executive officer arg2" "arg1 chief executive Sir arg2" "arg1 chief Sir arg2" "arg1 chief executive arg2" ] using (glaxosmithkline, andrew_witty)
• OE @1039 (100.0%) on 02-feb-2017 [ http://www.philly.com/philly/blogs/phillypharma/GlaxoSmithKlines-Andrew-Witty-says-1-billion-price-tag-for-drug-development-is-a-myth.html  ] using (andrew_witty, glaxosmithkline)
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~X0~concept:controlledbyagent" "Y~X0~concept:agentcontrols" "Y~_X0~concept:agentcontrols" "Y~X0~concept:superpartof" "Y~_X0~concept:superpartof" ] using (glaxosmithkline, andrew_witty)
• agentworkedondrug
• agenerase
• SEAL @241 (93.8%) on 22-apr-2011 [ 1 2 3 4 ] using (agenerase, glaxosmithkline)
• CPL @1094 (50.0%) on 01-jan-2018 [ "arg1 It is manufactured by arg2" ] using (agenerase, glaxosmithkline)
• albuterol
• SEAL @623 (100.0%) on 10-aug-2012 [ 1 2 ] using (albuterol, glaxosmithkline)
• argatroban
• SEAL @224 (87.5%) on 24-mar-2011 [ 1 2 3 ] using (argatroban, glaxosmithkline)
• avandamet
• CPL @1094 (75.0%) on 01-jan-2018 [ "arg1 is manufactured by arg2" "arg1 tablets manufactured by arg2" ] using (avandamet, glaxosmithkline)
• SEAL @263 (75.0%) on 22-may-2011 [ 1 2 ] using (avandamet, glaxosmithkline)
• avandia
• CPL @1094 (99.6%) on 01-jan-2018 [ "arg2 under the brand name arg1" "arg2 knew of the dangers of arg1" "arg2 had marketed arg1" "arg2 diabetes drug arg1" "arg2 under the trade name arg1" "arg2 is the manufacturer of arg1" "arg2 has struggled to maintain arg1" "arg2 aggressively marketed arg1" ] using (avandia, glaxosmithkline)
• OE @892 (93.7%) on 26-dec-2014 [ http://abcnews.go.com/topics/lifestyle/health/avandia.htm http://abcnews.go.com/topics/lifestyle/health/avandia.htm http://abcnews.go.com/topics/lifestyle/health/avandia.htm http://www.fiercepharma.com/tags/avandia http://abcnews.go.com/topics/lifestyle/health/avandia.htm http://www.yourlawyer.com/topics/overview/avandia http://www.yourlawyer.com/topics/overview/avandia http://www.yourlawyer.com/topics/overview/avandia  ] using (avandia, glaxosmithkline)
• SEAL @224 (87.5%) on 24-mar-2011 [ 1 2 3 ] using (avandia, glaxosmithkline)
• avodart
• SEAL @241 (75.0%) on 22-apr-2011 [ 1 2 ] using (avodart, glaxosmithkline)
• CPL @1094 (75.0%) on 01-jan-2018 [ "arg1 is manufactured by arg2" "arg1 is manufactured and marketed by arg2" ] using (avodart, glaxosmithkline)
• boniva
• CPL @1094 (75.0%) on 01-jan-2018 [ "arg1 from Roche and arg2" "arg1 is made jointly by arg2" ] using (boniva, glaxosmithkline)
• SEAL @310 (96.9%) on 21-jun-2011 [ 1 2 3 4 5 ] using (boniva, glaxosmithkline)
• cervarix
• OE @955 (90.5%) on 17-oct-2015 [ http://www.drugs.com/newdrugs/fda-approves-cervarix-glaxosmithkline-s-cervical-cancer-vaccine-1690.html http://gsk.co.nz/cervarix.html http://publico.gsk.es/productos/cervarix.html  ] using (cervarix, glaxosmithkline)
• SEAL @263 (98.4%) on 22-may-2011 [ 1 2 3 4 5 6 ] using (cervarix, glaxosmithkline)
• combivir
• SEAL @512 (96.9%) on 16-feb-2012 [ 1 2 3 4 5 ] using (combivir, glaxosmithkline)
• CPL @1094 (50.0%) on 01-jan-2018 [ "arg1 is marketed by arg2" ] using (combivir, glaxosmithkline)
• coreg
• SEAL @241 (75.0%) on 22-apr-2011 [ 1 2 ] using (coreg, glaxosmithkline)
• CPL @1094 (75.0%) on 01-jan-2018 [ "arg2 announces the availability of arg1" "arg2 received approval for arg1" ] using (coreg, glaxosmithkline)
• epivir
• CPL @1094 (50.0%) on 01-jan-2018 [ "arg1 is marketed by arg2" ] using (epivir, glaxosmithkline)
• SEAL @325 (87.5%) on 30-jun-2011 [ 1 2 3 ] using (epivir, glaxosmithkline)
• epzicom
• CPL @1094 (75.0%) on 01-jan-2018 [ "arg1 is manufactured by arg2" "arg1 is marketed by arg2" ] using (epzicom, glaxosmithkline)
• SEAL @512 (87.5%) on 16-feb-2012 [ 1 2 3 ] using (epzicom, glaxosmithkline)
• famvir
• SEAL @586 (50.0%) on 04-jun-2012 [ 1 ] using (famvir, glaxosmithkline)
• hycamptin
• OE @892 (100.0%) on 26-dec-2014 [ http://www.nature.com/nrd/journal/v10/n5/fig_tab/nrd3374_T2.html  ] using (hycamptin, glaxosmithkline)
• SEAL @310 (96.9%) on 21-jun-2011 [ 1 2 3 4 5 ] using (hycamptin, glaxosmithkline)
• hycamtin
• CPL @1094 (50.0%) on 01-jan-2018 [ "arg1 is manufactured by arg2" ] using (hycamtin, glaxosmithkline)
• SEAL @263 (87.5%) on 22-may-2011 [ 1 2 3 ] using (hycamtin, glaxosmithkline)
• imitrex
• SEAL @310 (100.0%) on 21-jun-2011 [ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 ] using (imitrex, glaxosmithkline)
• CPL @1094 (50.0%) on 01-jan-2018 [ "arg2 under the brand name arg1" ] using (imitrex, glaxosmithkline)
• lamictal
• SEAL @224 (93.8%) on 24-mar-2011 [ 1 2 3 4 ] using (lamictal, glaxosmithkline)
• CPL @1094 (75.0%) on 01-jan-2018 [ "arg1 is marketed by arg2" "arg1 usual by arg2" ] using (lamictal, glaxosmithkline)
• levitra
• CPL @1094 (75.0%) on 01-jan-2018 [ "arg1 is manufactured by arg2" "arg1 is marketed by arg2" ] using (levitra, glaxosmithkline)
• lotronex
• SEAL @310 (75.0%) on 21-jun-2011 [ 1 2 ] using (lotronex, glaxosmithkline)
• CPL @1094 (75.0%) on 01-jan-2018 [ "arg2 voluntarily withdrew arg1" "arg2 under the brand name arg1" ] using (lotronex, glaxosmithkline)
• nolvadex
• CPL @1100 (50.0%) on 31-jan-2018 [ "arg2 under the brand name arg1" ] using (nolvadex, glaxosmithkline)
• ondansetron
• CPL @1099 (50.0%) on 23-jan-2018 [ "arg1 was first manufactured by arg2" ] using (ondansetron, glaxosmithkline)
• orlistat
• CPL @1094 (50.0%) on 01-jan-2018 [ "arg1 is manufactured by arg2" ] using (orlistat, glaxosmithkline)
• paxil
• CPL @1094 (99.2%) on 01-jan-2018 [ "arg1 lawsuits filed against arg2" "arg1 is manufactured by arg2" "arg1 and its manufacturer arg2" "arg1 is manufactured arg2" "arg1 CR by arg2" "arg1 was first manufactured by arg2" "arg1 marketed by arg2" ] using (paxil, glaxosmithkline)
• OE @800 (87.8%) on 29-dec-2013 [ http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=beb15c4c-9ad8-4fa4-d28c-cef6ed9871b5 http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=beb15c4c-9ad8-4fa4-d28c-cef6ed9871b5 http://www.drugwatch.com/paxil/lawsuit.php http://en.wikipedia.org/wiki/Paroxetine http://www.drugwatch.com/paxil/lawsuit.php http://www.drugwatch.com/paxil/lawsuit.php http://www.forbes.com/sites/robwaters/2012/07/12/glaxosmithklines-3-billion-hit-deterrent-or-business-expense/ http://www.drugwatch.com/paxil/lawsuit.php  ] using (paxil, glaxosmithkline)
• SEAL @224 (93.8%) on 24-mar-2011 [ 1 2 3 4 ] using (paxil, glaxosmithkline)
• relenza
• SEAL @236 (87.5%) on 16-apr-2011 [ 1 2 3 ] using (relenza, glaxosmithkline)
• CPL @1094 (87.5%) on 01-jan-2018 [ "arg2 under the brand name arg1" "arg2 under the trade name arg1" "arg2 flu drug arg1" ] using (relenza, glaxosmithkline)
• sumatriptan
• CPL @1098 (50.0%) on 21-jan-2018 [ "arg1 is manufactured by arg2" ] using (sumatriptan, glaxosmithkline)
• tabloid
• OE @806 (100.0%) on 23-jan-2014 [  ] using (tabloid, glaxosmithkline)
• SEAL @611 (100.0%) on 09-jul-2012 [ 1 ] using (tabloid, glaxosmithkline)
• tagamet
• SEAL @523 (100.0%) on 02-mar-2012 [ 1 ] using (tagamet, glaxosmithkline)
• CPL @1094 (75.0%) on 01-jan-2018 [ "arg2 under the brand name arg1" "arg2 under the trade name arg1" ] using (tagamet, glaxosmithkline)
• tagamet_hb_200
• SEAL @539 (100.0%) on 26-mar-2012 [ 1 ] using (tagamet_hb_200, glaxosmithkline)
• trizivir
• SEAL @269 (100.0%) on 24-may-2011 [ 1 ] using (trizivir, glaxosmithkline)
• OE @809 (100.0%) on 01-feb-2014 [  ] using (trizivir, glaxosmithkline)
• CPL @1094 (75.0%) on 01-jan-2018 [ "arg1 is marketed by arg2" "arg1 is manufactured by arg2" ] using (trizivir, glaxosmithkline)
• valtrex
• OE @949 (100.0%) on 20-sep-2015 [ http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f8e0d8f8-cb73-4206-a484-88f5c4fbd719 http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f8e0d8f8-cb73-4206-a484-88f5c4fbd719 http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f8e0d8f8-cb73-4206-a484-88f5c4fbd719 http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f8e0d8f8-cb73-4206-a484-88f5c4fbd719  ] using (valtrex, glaxosmithkline)
• CPL @1095 (50.0%) on 17-jan-2018 [ "arg1 is manufactured by arg2" ] using (valtrex, glaxosmithkline)
• SEAL @241 (98.4%) on 22-apr-2011 [ 1 2 3 4 5 6 ] using (valtrex, glaxosmithkline)
• ziagen
• SEAL @269 (93.8%) on 24-may-2011 [ 1 2 3 4 ] using (ziagen, glaxosmithkline)
• zofran
• CPL @1094 (75.0%) on 01-jan-2018 [ "arg1 is manufactured by arg2" "arg1 was first manufactured by arg2" ] using (zofran, glaxosmithkline)
• OE @892 (100.0%) on 26-dec-2014 [ http://en.wikipedia.org/wiki/Ondansetron  ] using (zofran, glaxosmithkline)
• SEAL @224 (99.2%) on 24-mar-2011 [ 1 2 3 4 5 6 7 ] using (zofran, glaxosmithkline)
• zovirax
• SEAL @269 (93.8%) on 24-may-2011 [ 1 2 3 4 ] using (zovirax, glaxosmithkline)
• zyban
• SEAL @263 (50.0%) on 22-may-2011 [ 1 ] using (zyban, glaxosmithkline)
• cityhasstreet
• north
• CPL @1108 (50.0%) on 07-jun-2018 [ "arg1 Carolina and arg2" ] using (north, glaxosmithkline)
• companyceo
• andrew_witty
• CPL @1094 (96.9%) on 01-jan-2018 [ "arg2 boss arg1" "arg2 chief executive officer arg1" "arg2 chief executive Sir arg1" "arg2 chief Sir arg1" "arg2 chief executive arg1" ] using (andrew_witty, glaxosmithkline)
• controlledbyagent
• andrew_witty
• SEAL @359 (99.6%) on 23-jul-2011 [ 1 2 3 4 5 6 7 8 ] using (andrew_witty, glaxosmithkline)
• OE @826 (100.0%) on 28-mar-2014 [   ] using (andrew_witty, glaxosmithkline)
• mutualproxyfor
• andrew_witty
• SEAL @566 (93.8%) on 12-may-2012 [ 1 2 3 4 ] using (andrew_witty, glaxosmithkline)
• OE @1039 (100.0%) on 02-feb-2017 [ http://www.philly.com/philly/blogs/phillypharma/GlaxoSmithKlines-Andrew-Witty-says-1-billion-price-tag-for-drug-development-is-a-myth.html  ] using (glaxosmithkline, andrew_witty)
• SEAL @566 (93.8%) on 12-may-2012 [ 1 2 3 4 ] using (glaxosmithkline, andrew_witty)
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~_X0~concept:superpartof" "Y~X0~concept:superpartof" "Y~_X0~concept:superpartof,concept:subpartof,concept:superpartof" "Y~X0~concept:controlledbyagent" "Y~_X0~concept:agentcontrols" ] using (andrew_witty, glaxosmithkline)
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~_X0~concept:superpartof" "Y~X0~concept:superpartof" "Y~_X0~concept:superpartof,concept:subpartof,concept:superpartof" "Y~X0~concept:controlledbyagent" "Y~_X0~concept:agentcontrols" ] using (glaxosmithkline, andrew_witty)
• OE @1039 (100.0%) on 02-feb-2017 [ http://www.philly.com/philly/blogs/phillypharma/GlaxoSmithKlines-Andrew-Witty-says-1-billion-price-tag-for-drug-development-is-a-myth.html  ] using (andrew_witty, glaxosmithkline)
• organizationhasagent
• andrew_witty
• CPL @1099 (93.8%) on 23-jan-2018 [ "arg2 chief executive officer arg1" "arg2 chief executive Sir arg1" "arg2 chief Sir arg1" "arg2 chief executive arg1" ] using (andrew_witty, glaxosmithkline)
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~X0~concept:agentcontrols,concept:relatedto,concept:agenthierarchicallybelowagent" "Y~X0~concept:agentcontrols,concept:relatedto,concept:controlledbyagent" "Y~X0~concept:agentcontrols,concept:relatedto,concept:agentinteractswithagent" "Y~_X0~concept:proxyfor" "Y~X0~concept:agentcontrols,concept:relatedto,concept:agentcollaborateswithagent" ] using (andrew_witty, glaxosmithkline)
• OE @985 (89.2%) on 17-mar-2016 [ http://articles.economictimes.indiatimes.com/2013-11-18/news/44202459_1_gsk-india-pricing-all-india-organisation http://www.huffingtonpost.co.uk/2013/12/02/glaxosmithkline-china-davidcameron_n_4370643.html https://www.gov.uk/government/news/give-universities-bigger-role-in-growing-economy-witty http://www.businessweek.com/articles/2013-07-17/glaxosmithklines-andrew-witty-on-fixing-big-pharmas-bad-boy http://www.fiercebiotech.com/special-reports/25-most-influential-people-biopharma-today/sir-andrew-witty-25-most-influential-peop http://www.express.co.uk/finance/city/415561/Andrew-Witty-to-quit-key-role-at-GlaxoSmithKline  ] using (andrew_witty, glaxosmithkline)
• organizationhasperson
• andrew_witty
• CPL @1103 (93.8%) on 06-mar-2018 [ "arg2 chief executive officer arg1" "arg2 chief executive Sir arg1" "arg2 chief Sir arg1" "arg2 chief executive arg1" ] using (andrew_witty, glaxosmithkline)
• OE @965 (100.0%) on 17-dec-2015 [ http://www.huffingtonpost.co.uk/2013/12/02/glaxosmithkline-china-davidcameron_n_4370643.html http://www.fiercebiotech.com/special-reports/25-most-influential-people-biopharma-today/sir-andrew-witty-25-most-influential-peop https://www.gov.uk/government/news/give-universities-bigger-role-in-growing-economy-witty http://www.businessweek.com/articles/2013-07-17/glaxosmithklines-andrew-witty-on-fixing-big-pharmas-bad-boy http://articles.economictimes.indiatimes.com/2013-11-18/news/44202459_1_gsk-india-pricing-all-india-organisation http://www.express.co.uk/finance/city/415561/Andrew-Witty-to-quit-key-role-at-GlaxoSmithKline  ] using (andrew_witty, glaxosmithkline)
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~_X0~concept:agentleadsorganization" "Y~_X0~concept:agentrepresentsorganization" "Y~_X0~concept:personleadsorganization" "Y~_X0~concept:mutualproxyfor" "Y~_X0~concept:proxyfor" ] using (andrew_witty, glaxosmithkline)
• organizationhastopmember
• andrew_witty
• CPL @1096 (93.8%) on 18-jan-2018 [ "arg2 chief executive officer arg1" "arg2 chief executive Sir arg1" "arg2 chief Sir arg1" "arg2 chief executive arg1" ] using (andrew_witty, glaxosmithkline)
• organizationleadbyperson
• andrew_witty
• CPL @1094 (96.9%) on 01-jan-2018 [ "arg2 boss arg1" "arg2 chief executive officer arg1" "arg2 chief executive Sir arg1" "arg2 chief Sir arg1" "arg2 chief executive arg1" ] using (andrew_witty, glaxosmithkline)
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~_X0~concept:personbelongstoorganization" "Y~X0~concept:personbelongstoorganization" "Y~X0~concept:personbelongstoorganization,concept:organizationleadbyperson,concept:personbelongstoorganization" "Y~X0~concept:personbelongstoorganization,concept:organizationleadbyagent,concept:personbelongstoorganization" "Y~X0~concept:personbelongstoorganization,concept:proxyof,concept:personbelongstoorganization" ] using (andrew_witty, glaxosmithkline)
• SEAL @190 (99.2%) on 16-jan-2011 [ 1 2 3 4 5 6 7 ] using (andrew_witty, glaxosmithkline)
• OE @886 (100.0%) on 12-nov-2014 [ http://articles.economictimes.indiatimes.com/2013-11-18/news/44202459_1_gsk-india-pricing-all-india-organisation https://www.gov.uk/government/news/give-universities-bigger-role-in-growing-economy-witty http://www.youtube.com/watch?v=-K1SdY8vpwo http://www.businessweek.com/articles/2013-07-17/glaxosmithklines-andrew-witty-on-fixing-big-pharmas-bad-boy http://www.forbes.com/sites/matthewherper/2013/10/29/can-this-man-make-you-believe-in-drug-companies/ http://www.fiercebiotech.com/special-reports/25-most-influential-people-biopharma-today/sir-andrew-witty-25-most-influential-peop http://www.huffingtonpost.co.uk/2013/12/02/glaxosmithkline-china-davidcameron_n_4370643.html  ] using (andrew_witty, glaxosmithkline)
• proxyof
• andrew_witty
• CPL @1103 (87.5%) on 06-mar-2018 [ "arg2 chief executive officer arg1" "arg2 chief executive Sir arg1" "arg2 chief executive arg1" ] using (andrew_witty, glaxosmithkline)
• SEAL @551 (87.5%) on 10-apr-2012 [ 1 2 3 ] using (andrew_witty, glaxosmithkline)
• synonymfor
• department
• CPL @1105 (50.0%) on 25-mar-2018 [ "arg1 of Trade and Industry and arg2" ] using (department, glaxosmithkline)
• CPL @1105 (50.0%) on 25-mar-2018 [ "arg1 of Trade and Industry and arg2" ] using (glaxosmithkline, department)
• worker
• andrew_witty
• SEAL @521 (93.8%) on 28-feb-2012 [ 1 2 3 4 ] using (andrew_witty, glaxosmithkline)
• CPL @1103 (93.8%) on 06-mar-2018 [ "arg2 chief executive officer arg1" "arg2 chief executive Sir arg1" "arg2 chief Sir arg1" "arg2 chief executive arg1" ] using (andrew_witty, glaxosmithkline)
• OE @968 (86.1%) on 29-dec-2015 [ http://articles.economictimes.indiatimes.com/2013-11-18/news/44202459_1_gsk-india-pricing-all-india-organisation https://www.gov.uk/government/news/give-universities-bigger-role-in-growing-economy-witty http://www.huffingtonpost.co.uk/2013/12/02/glaxosmithkline-china-davidcameron_n_4370643.html http://www.businessweek.com/articles/2013-07-17/glaxosmithklines-andrew-witty-on-fixing-big-pharmas-bad-boy http://www.fiercebiotech.com/special-reports/25-most-influential-people-biopharma-today/sir-andrew-witty-25-most-influential-peop http://www.express.co.uk/finance/city/415561/Andrew-Witty-to-quit-key-role-at-GlaxoSmithKline  ] using (andrew_witty, glaxosmithkline)
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~X0~concept:personleadsorganization,concept:worker,concept:agentleadsorganization" "Y~_X0~concept:agentleadsorganization" "Y~_X0~concept:agentrepresentsorganization" "Y~_X0~concept:personleadsorganization" "Y~_X0~concept:agentcontrols" ] using (andrew_witty, glaxosmithkline)
• publicationjournalist
• david001
• CPL @1112 (50.0%) on 20-jul-2018 [ "arg1 Stout of arg2" ] using (david, glaxosmithkline)